Eli Lilly's next-generation obesity drug retatrutide helped significantly reduce A1C levels for people with diabetes while helping them lose weight.

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

Lowering your A1C can significantly reduce your risk of heart disease. You can lower your A1C by eating more fiber and protein, cutting back on refined carbs, and more.

Eli Lilly 3rd-generation GLP-1 retatrutide lowers A1C by 1.9% and reduces body weight by 33.3 pounds in phase 3 trial.

Add Yahoo as a preferred source to see more of our stories on Google. If you’ve ever had your blood sugar tested, chances are you’ve heard your doctor mention your A1C. This simple blood test gives a ...

Lilly says its experimental drug retatrutide met the primary endpoint and key secondary endpoints in a new study.

Hemoglobin A1C is a blood test that measures the average amount of glucose (sugar) in your blood over the last three months. “When blood sugar levels stay elevated over time, it causes A1C to increase ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...

Should A1c remain the gold standard for routine monitoring of glucose control in people with diabetes, or is it time to shift ...

The math might seem simple. Unhealthy diet plus no exercise equals heart trouble. But as it turns out, high levels of low-density lipoprotein (LDL) cholesterol (the variety they call bad) isn’t the ...

The morning was slipping away as Rose Weinstein sat on her couch, trying to gather the energy to start her day. The Indianapolis grandmother had hours of errands ahead of her, but despite the ticking ...